Article
Excerpt from the Press Release: BOSTON, March 23, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the…
Read More
Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing Activity Phase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the Treatment of Relapsed/Refractory Multiple Myeloma BCMA Program Clinical Update Expected by the End of 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 23,…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing led by Lightspeed Venture Partners. The company licensed its lead compound, KRLS-017, from Ube Industries, Ltd., a premier Japanese chemical manufacturer. The company also completed…
Read More
Senior leaders in science, government, and industry recruited for international “Manhattan Project for the Brain” Excerpt from the Press Release: DUBAI, United Arab Emirates & PALO ALTO, Calif. & MONTREAL–(BUSINESS WIRE)–Neurotechnology Powerhouse NeuroVigil (ranked “Top 10 most innovative companies in health care” by Washington Post and Fast Company) announced at the New Technology & Mental…
Read More
Excerpt from the Press Release: SAN JOSE, Calif.–(BUSINESS WIRE)–Broncus Medical (02216HK), Inc., developer of diagnostic and therapeutic technology for a variety of lung diseases, today announced online publication in the Respirology journal of a global, multicenter study demonstrating the effectiveness of the company’s Archimedes® Virtual Bronchoscopic Navigation (VBN) System in guiding the sampling of peripheral…
Read More
CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) as…
Read More
Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without concomitant cataract surgery. Excerpt from the Press Release: MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative…
Read More
BioFluidica LiquidScan Next-Generation Testing Platform, Can Detect Diseases in 15 Minutes Excerpt from the Press Release: SAN DIEGO, March 23, 2022 /PRNewswire/ — BioFluidica, a privately held biotechnology company, today announced they have been awarded a continuation grant from the Midwest Biomedical Accelerator Research Consortium (MBArC) on behalf of the National Institutes of Health Rapid Acceleration of…
Read More
First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep’s development in large and rapidly growing pharmaceutical markets, including China, Hong Kong, Macau, Taiwan, Singapore, and South Korea Final cohort’s dosing regimen is equivalent to Oncolytics’ North American phase 2 trial in…
Read More
Excerpt from the Press Release: DEL MAR, Calif,, March 23, 2022 /PRNewswire/ — Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. The current vaccines offer limited protection over time against the omicron variant that is now dominating…
Read More